Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 225 Franklin Street, 26Th Floor BOSTON MA 02110 |
Tel: | N/A |
Website: | https://www.pieris.com |
IR: | See website |
Key People | ||
Stephen S. Yoder President, Chief Executive Officer, Director | Thomas Bures Chief Financial Officer, Senior Vice President | Hitto Kaufmann Senior Vice President, Chief Scientific Officer | Shane Olwill Senior Vice President, Chief Development Officer |
Business Overview |
Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways. The Company's clinical pipeline includes an inhaled IL-4Ra antagonist Anticalin protein to treat asthma, an immuno-oncology (IO), bispecific targeting HER2 and 4-1BB, and an IO bispecific targeting PD-L1 and 4-1BB. Its lead respiratory Anticalin based drug candidate, elarekibep, antagonizes IL-4Ra, thereby inhibiting IL-4 and IL-13, two cytokines, which are small proteins mediating signaling between cells within the human body, known to be key mediators in the inflammatory cascade that drive the pathogenesis of asthma and other inflammatory diseases. Its IO portfolio also includes additional drug candidates beyond PRS-344/S095012 that are multi-specific Anticalin-based fusion proteins designed to engage immunomodulatory targets, comprising a variety of multifunctional biotherapeutics. |
Financial Overview |
For the nine months ended 30 September 2023, Pieris Pharmaceuticals Inc revenues increased from $20.1M to $41.5M. Net loss decreased 21% to $20M. Revenues reflect Customer revenue increase of 91% to $37.7M, Collaboration revenue increase from $296K to $3.8M. Lower net loss reflects Research and development decrease of 6% to $37.3M (expense), Interest income increase from $373K to $1.4M (income). |
Employees: | 127 as of Dec 31, 2022 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | N/A |
Annual revenue (TTM): | $47.36M as of Sep 30, 2023 |
EBITDA (TTM): | -$12.40M as of Sep 30, 2023 |
Net annual income (TTM): | -$28.06M as of Sep 30, 2023 |
Free cash flow (TTM): | -$47.26M as of Sep 30, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 98,851,927 as of Nov 9, 2023 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |